Purchase
Description
Ipilimumab biosimilaris a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.
Ipilimumab biosimilar is supplied at a concentration of 5 mg/mL as a sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution of pH 7.0, which contains 0.04 mg/mL diethylene triamine pentaacetic acid (DTPA), 10 mg/mL mannitol, 0.1 mg/mL polysorbate 80 (vegetable origin), 5.85 mg/mL sodium chloride, 3.15 mg/mL tris hydrochloride.
Statement: this product is used for R&D only, not for clinical usage.
Properties
|
Name
|
Ipilimumab biosimilar
|
|
CAS
NO.
|
477202-00-9
|
|
Type
|
Whole
antibody
|
|
Source
|
Human
|
|
Target
|
CTLA-4
|
|
Clone
|
Monoclone
|
|
Molecular
Weight
|
148 kDa
|
|
Formula
|
C6742H9972N1732O2004S40
|
|
Antibody
Form
|
Purified immunoglobulin
|
|
Physical
Form
|
Solution
|
|
Grade
Standard
|
Medicine Grade
|
|
Storage
|
-70±15℃ for long-term
storage, 2-8℃ for short-term storage, away from light.
|
Supply Ability
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
/en/UploadFile/file/201805/20180508154382758275.rar
Detail information about the product please refer the website below：
https://en.wikipedia.org/wiki/Ipilimumab
|
